

Resource Summary Report

Generated by [NIF](#) on Jul 30, 2026

MEK1/2 (D1A5) Rabbit mAb

RRID:AB_10829473

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 8727, RRID:AB_10829473

Antibody Information

URL: http://antibodyregistry.org/AB_10829473

Proper Citation: Cell Signaling Technology Cat# 8727, RRID:AB_10829473

Target Antigen: MEK1/2 (D1A5) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IF-IC, F

Antibody Name: MEK1/2 (D1A5) Rabbit mAb

Description: This monoclonal targets MEK1/2 (D1A5) Rabbit mAb

Target Organism: b, dg, rat, ce), hamster, h, porcine, dm, c. elegans/worm, canine, m, (hm, mouse, r, non-human primate, drosophila/arthropod, pg, x, bovine, z, human, mk

Antibody ID: AB_10829473

Vendor: Cell Signaling Technology

Catalog Number: 8727

Alternative Catalog Numbers: 8727S

Record Creation Time: 20250820T002813+0000

Record Last Update: 20250820T082113+0000

Ratings and Alerts

No rating or validation information has been found for MEK1/2 (D1A5) Rabbit mAb.

No alerts have been found for MEK1/2 (D1A5) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 37 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Diamond EL, et al. (2026) RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition. *Cancer cell*, 44(1), 203.

Burge RA, et al. (2025) PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer. *Cancer research*, OF1.

O'Keefe ME, et al. (2025) Restraint of inflammasome-driven cytokine responses through the mRNA stability protein TTP. *Cell reports*, 44(3), 115340.

Borbényi-Galampos K, et al. (2025) Realigned transsulfuration drives BRAF-V600E-targeted therapy resistance in melanoma. *Cell metabolism*, 37(5), 1171.

Shemorry A, et al. (2025) Engineering ER γ degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases. *Cell chemical biology*, 32(5), 694.

Theardy MS, et al. (2025) Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. *Cell reports. Medicine*, 6(8), 102253.

Ma W, et al. (2025) TAOK2 controls synaptic plasticity and anxiety via ERK and calcium signaling. *iScience*, 28(11), 113712.

Walter Z, et al. (2025) An integrated proteomics approach identifies phosphorylation sites on viral and host proteins that regulate West Nile virus infection. *Cell reports*, 44(5), 115728.

Nokin MJ, et al. (2024) In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma. *Cell reports. Medicine*, 5(8), 101663.

Morshed S, et al. (2024) The TSH Receptor Antibody Reactome Contributes to Retro-Orbital Inflammation. *Journal of the Endocrine Society*, 8(12), bvae182.

Sadeghi M, et al. (2024) Biased signaling by mutant EGFR underlies dependence on PKC γ in lung adenocarcinoma. *Cell reports*, 43(12), 115026.

Chen Y, et al. (2024) Cancer-Associated Endocrine Cells Participate in Pancreatic Carcinogenesis. *Gastroenterology*, 167(6), 1167.

Wang J, et al. (2024) LILRB1-HLA-G axis defines a checkpoint driving natural killer cell exhaustion in tuberculosis. *EMBO molecular medicine*, 16(8), 1755.

Zheng H, et al. (2024) PDGFR α +ITGA11+ fibroblasts foster early-stage cancer lymphovascular invasion and lymphatic metastasis via ITGA11-SELE interplay. *Cancer cell*.

Martín-Vega A, et al. (2023) Scaffold coupling: ERK activation by trans-phosphorylation across different scaffold protein species. *Science advances*, 9(7), eadd7969.

Hondo N, et al. (2023) MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells. *Cancer letters*, 567, 216264.

Ta L, et al. (2023) Wild-type C-Raf gene dosage and dimerization drive prostate cancer metastasis. *iScience*, 26(12), 108480.

Xu X, et al. (2023) Sox10 escalates vascular inflammation by mediating vascular smooth muscle cell transdifferentiation and pyroptosis in neointimal hyperplasia. *Cell reports*, 42(8), 112869.

Gao X, et al. (2022) Lyso-PAF, a biologically inactive phospholipid, contributes to RAF1 activation. *Molecular cell*, 82(11), 1992.

Leung W, et al. (2022) SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis. *Cancer discovery*, 12(7), 1782.